Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL2702 (Tamsulosin 0.4mg) vs Harnal-D in BPH Patients
NCT02303769Phase 3Completed
- Sponsor
- GL Pharm Tech Corp
- Start
- Mar 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GL Pharm Tech Corp. Primary endpoint: International Prostate Symptom Score at 8 weeks. Started Mar 2014; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02303769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303769.